260
A. S. Shinde et al.
Table 1
(continued)
Drug/active ingredients System components
Aim
Major applications
Route of
administration
Paclitaxel
P(GLU)
To improve the
solubility of the
drug
Improved therapeutics and
reduced toxicity
In vitro
Mesoporous
silica
Nanoparticle
Cyclosporin A
Tetraethyl Orthosilicate
To improve the
solubility of the
drug
Increased solubility,
bioavailability, and
enhanced absorption
Oral delivery
siRNA
Poly ethylenimine
To effective deliver
siRNA and stable
Highly stable, highly
effective siRNA delivery
with optimal cellular
integration and low toxicity
In vitro
Doxorubicin
Cetyltrimethylammonium bromide
(CTAB)
To sustained release Increased biocompatibility
and low toxicity
In vitro
Docetaxel
Lactose
To targeted delivery Increased bioavailability
and site-specific delivery
In vitro
Chitosan
Nanoparticle
Ethosuximide
Chitosan
To sustained release Extended-release of drug
and excellent cytotoxicity
In vivo
and
in vitro
5-Fluorouracil
Chitosan
To prevent drug
degradation
Preventing drug degradation
at gastric pH and effective
delivery of the drug in
site-specific
Oral delivery
Idebenone
Chitosan and N- carboxymethyl
chitosan
To increase stability Increased stability and
reduced mucose membrane
irritation
In vitro-topical
or nasal
(continued)